Samsrita Labs Limited Stock

Equities

DRHABEEB

INE579N01018

Healthcare Facilities & Services

Market Closed - Bombay S.E. 06:00:55 2024-05-03 EDT 5-day change 1st Jan Change
17.1 INR +2.46% Intraday chart for Samsrita Labs Limited -1.72% -1.33%

Financials

Sales 2022 225K 2.69K 3.69K Sales 2023 217K 2.6K 3.56K Capitalization 331M 3.97M 5.44M
Net income 2022 15M 180K 246K Net income 2023 -7M -83.9K -115K EV / Sales 2022 2,001 x
Net Debt 2022 27.31M 327K 448K Net Debt 2023 20.7M 248K 340K EV / Sales 2023 1,623 x
P/E ratio 2022
28.2 x
P/E ratio 2023
-46.6 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 36.47%
More Fundamentals * Assessed data
Dynamic Chart
Samsrita Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Samsrita Labs Limited Announces Resignation of Aakauskha as Independent Director CI
Samsrita Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Samsrita Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Samsrita Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Samsritalabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Samsritalabs Limited Reports Earnings Results for the Second Quarter and Half Year Ended September 30, 2022 CI
Samsritalabs Limited Reports Earnings Results for the Half Year Ended September 30, 2022 CI
Dr Habeebullah Life Sciences Limited has Changed its Name to SAMSRITALABS LIMITED CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the First quarter Ended June 30, 2021 CI
Dr Habeebullah Life Sciences Limited Announces Change in Registered Office and Corporate Office Address CI
Dr Habeebullah Life Sciences Limited Announces Management Changes CI
Dr Habeebullah Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
More news
1 day+2.46%
1 week-1.72%
Current month+1.30%
1 month+16.49%
3 months+0.59%
6 months+0.88%
Current year-1.33%
More quotes
1 week
16.30
Extreme 16.3
17.79
1 month
14.10
Extreme 14.1
18.05
Current year
13.00
Extreme 13
18.50
1 year
13.00
Extreme 13
22.00
3 years
13.00
Extreme 13
44.15
5 years
13.00
Extreme 13
75.50
10 years
7.00
Extreme 7
75.50
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 20-02-13
Chairman 65 16-12-25
Chief Administrative Officer 60 19-03-31
Members of the board TitleAgeSince
Chairman 65 16-12-25
Director/Board Member - 19-03-21
Director/Board Member 56 21-06-28
More insiders
Date Price Change Volume
24-05-03 17.1 +2.46% 955
24-05-02 16.69 -1.13% 8,363
24-04-30 16.88 +0.72% 5,168
24-04-29 16.76 -3.68% 12,497
24-04-26 17.4 +4.50% 756

Delayed Quote Bombay S.E., May 03, 2024 at 06:00 am

More quotes
Samsrita Labs Ltd is an India-based biopharma company. The Company is engaged activities, such as trading, exports and imports, manufacturing of bulk drugs, APIs, Specialty drugs, research and development (R&D) through joint ventures or associations or mergers or by its own. It has established platforms in the areas of stem cell research and therapy, new drug discovery, molecular prognosis and diagnostics services, CRO, stem cell focused super specialty hospital, RNA interference technology and medical devices. Its Stem Cell R&D division specializes in stem cell research and therapy, regenerative medicine, bio-artificial organ scaffolds development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology, stem cell and cord blood banking. Its New Drug Discovery division is focused on working on five therapeutic areas of Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiovascular diseases, cystinosis and Huntington's disease.
More about the company
  1. Stock Market
  2. Equities
  3. DRHABEEB Stock